주의력결핍 과잉행동장애 아동에서 공존질환에 따른 OROS-Methylphenidate의 효과와 안전성

Efficacy and Tolerability of Osmotic Release Oral System-Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder According to Comorbid Psychiatric Disorders

Objectives : The purpose of this study is to evaluate the efficacy and tolerability of OROS-Methylphenidate(MPH) in children with Attention Deficit Hyperactivity Disorder(ADHD) according to comorbid psychiatric disorders. Methods : This is an 8-week open label study of OROS-MPH monotherapy. Subjects were 6-12 years of aged 113 children with ADHD. Outcome measures were Korean version parent ADHD rating scale(K-ARS), Korean version Conners parent rating scale(K-CPRS), Clinical Global Impression-Severity and Clinical Global Impression -Improvement. Side effects were monitored with the Barkley’s side effect rating scale. We compared change-over-time of mean scores of outcome measure according to comorbidity of disruptive behavior disorder, depressive disorder, anxiety disorder, and tic disorder. Results : Mean scores of K-ARS and K-CPRS were significantly decreased regardless of comorbidity. Mean doses of OROS-MPH and dropout rate were not different significantly according to comorbidity. For side effects, overall OROS-MPH was well tolerated despite comorbidity. However, children with tic disorder reported higher tics or nervous movements item than those without tic disorder from 2nd week to 8th week. Conclusion: OROS-MPH is efficacious for decreasing the symptoms of ADHD and well tolerated regardless of comorbid psychiatric disorders.

Objectives : The purpose of this study is to evaluate the efficacy and tolerability of OROS-Methylphenidate(MPH) in children with Attention Deficit Hyperactivity Disorder(ADHD) according to comorbid psychiatric disorders. Methods : This is an 8-week open label study of OROS-MPH monotherapy. Subjects were 6-12 years of aged 113 children with ADHD. Outcome measures were Korean version parent ADHD rating scale(K-ARS), Korean version Conners parent rating scale(K-CPRS), Clinical Global Impression-Severity and Clinical Global Impression -Improvement. Side effects were monitored with the Barkley’s side effect rating scale. We compared change-over-time of mean scores of outcome measure according to comorbidity of disruptive behavior disorder, depressive disorder, anxiety disorder, and tic disorder. Results : Mean scores of K-ARS and K-CPRS were significantly decreased regardless of comorbidity. Mean doses of OROS-MPH and dropout rate were not different significantly according to comorbidity. For side effects, overall OROS-MPH was well tolerated despite comorbidity. However, children with tic disorder reported higher tics or nervous movements item than those without tic disorder from 2nd week to 8th week. Conclusion: OROS-MPH is efficacious for decreasing the symptoms of ADHD and well tolerated regardless of comorbid psychiatric disorders.